Avalyn Pharma Inc.

AVLN Nasdaq SEC CIK 1540171
Follow Avalyn Pharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$29.7M −25.7% vs same quarter last year
EPS, diluted −$0.67 +96.7% vs same quarter last year
Operating cash flow −$26.3M −51.8% vs same quarter last year
Operating income −$33.1M −30.7% vs same quarter last year
Net income by quarter
−$17.5M
−$20.2M
−$23.6M
−$26.9M
−$28.9M
−$29.7M
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing